Drug profile · INN
haloperidol decanoate
HALDOL DECANOATE
haloperidol decanoate (HALDOL DECANOATE) is a d2-like dopamine receptor inverse agonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — haloperidol decanoate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
haloperidol decanoate (HALDOL DECANOATE) is a d2-like dopamine receptor inverse agonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
D2-like dopamine receptor inverse agonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is haloperidol decanoate?
haloperidol decanoate (HALDOL DECANOATE) is a d2-like dopamine receptor inverse agonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for haloperidol decanoate?
HALDOL DECANOATE is a marketed brand name for haloperidol decanoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of haloperidol decanoate?
haloperidol decanoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.